158 related articles for article (PubMed ID: 18383466)
21. Phosphorylation of the immunomodulatory drug FTY720 by sphingosine kinases.
Billich A; Bornancin F; Dévay P; Mechtcheriakova D; Urtz N; Baumruker T
J Biol Chem; 2003 Nov; 278(48):47408-15. PubMed ID: 13129923
[TBL] [Abstract][Full Text] [Related]
22. FTY720 and (S)-FTY720 vinylphosphonate inhibit sphingosine kinase 1 and promote its proteasomal degradation in human pulmonary artery smooth muscle, breast cancer and androgen-independent prostate cancer cells.
Tonelli F; Lim KG; Loveridge C; Long J; Pitson SM; Tigyi G; Bittman R; Pyne S; Pyne NJ
Cell Signal; 2010 Oct; 22(10):1536-42. PubMed ID: 20570726
[TBL] [Abstract][Full Text] [Related]
23. The sphingosine 1-phosphate receptor agonist FTY720 potently inhibits regulatory T cell proliferation in vitro and in vivo.
Wolf AM; Eller K; Zeiser R; Dürr C; Gerlach UV; Sixt M; Markut L; Gastl G; Rosenkranz AR; Wolf D
J Immunol; 2009 Sep; 183(6):3751-60. PubMed ID: 19692647
[TBL] [Abstract][Full Text] [Related]
24. In vitro evaluation of the effect of a novel immunosuppressive agent, FTY720, on the function of feline neutrophils.
Chen YJ; Kyles AE; Gregory CR
Am J Vet Res; 2006 Apr; 67(4):588-92. PubMed ID: 16579750
[TBL] [Abstract][Full Text] [Related]
25. Genetic, biochemical, and transcriptional responses of Saccharomyces cerevisiae to the novel immunomodulator FTY720 largely mimic those of the natural sphingolipid phytosphingosine.
Welsch CA; Roth LW; Goetschy JF; Movva NR
J Biol Chem; 2004 Aug; 279(35):36720-31. PubMed ID: 15190065
[TBL] [Abstract][Full Text] [Related]
26. Brain sphingosine-1-phosphate receptors: implication for FTY720 in the treatment of multiple sclerosis.
Dev KK; Mullershausen F; Mattes H; Kuhn RR; Bilbe G; Hoyer D; Mir A
Pharmacol Ther; 2008 Jan; 117(1):77-93. PubMed ID: 17961662
[TBL] [Abstract][Full Text] [Related]
27. Chiral vinylphosphonate and phosphonate analogues of the immunosuppressive agent FTY720.
Lu X; Sun C; Valentine WJ; Shuyu E; Liu J; Tigyi G; Bittman R
J Org Chem; 2009 Apr; 74(8):3192-5. PubMed ID: 19296586
[TBL] [Abstract][Full Text] [Related]
28. Accumulation of fingolimod (FTY720) in lymphoid tissues contributes to prolonged efficacy.
Sensken SC; Bode C; Gräler MH
J Pharmacol Exp Ther; 2009 Mar; 328(3):963-9. PubMed ID: 19074680
[TBL] [Abstract][Full Text] [Related]
29. Sphingosine and FTY720 are potent inhibitors of the transient receptor potential melastatin 7 (TRPM7) channels.
Qin X; Yue Z; Sun B; Yang W; Xie J; Ni E; Feng Y; Mahmood R; Zhang Y; Yue L
Br J Pharmacol; 2013 Mar; 168(6):1294-312. PubMed ID: 23145923
[TBL] [Abstract][Full Text] [Related]
30. FTY720, a sphingosine-1-phosphate receptor modulator, reverses high-fat diet-induced weight gain, insulin resistance and adipose tissue inflammation in C57BL/6 mice.
Kendall MR; Hupfeld CJ
Diabetes Obes Metab; 2008 Sep; 10(9):802-5. PubMed ID: 18494802
[No Abstract] [Full Text] [Related]
31. Involvement of vacuolar H(+)-ATPase in killing of human melanoma cells by the sphingosine kinase analogue FTY720.
Tay KH; Liu X; Chi M; Jin L; Jiang CC; Guo ST; Verrills NM; Tseng HY; Zhang XD
Pigment Cell Melanoma Res; 2015 Mar; 28(2):171-83. PubMed ID: 25358761
[TBL] [Abstract][Full Text] [Related]
32. Constrained azacyclic analogues of the immunomodulatory agent FTY720 as molecular probes for sphingosine 1-phosphate receptors.
Hanessian S; Charron G; Billich A; Guerini D
Bioorg Med Chem Lett; 2007 Jan; 17(2):491-4. PubMed ID: 17070046
[TBL] [Abstract][Full Text] [Related]
33. Active, phosphorylated fingolimod inhibits histone deacetylases and facilitates fear extinction memory.
Hait NC; Wise LE; Allegood JC; O'Brien M; Avni D; Reeves TM; Knapp PE; Lu J; Luo C; Miles MF; Milstien S; Lichtman AH; Spiegel S
Nat Neurosci; 2014 Jul; 17(7):971-80. PubMed ID: 24859201
[TBL] [Abstract][Full Text] [Related]
34. FTY720/fingolimod, a sphingosine analogue, reduces amyloid-β production in neurons.
Takasugi N; Sasaki T; Ebinuma I; Osawa S; Isshiki H; Takeo K; Tomita T; Iwatsubo T
PLoS One; 2013; 8(5):e64050. PubMed ID: 23667698
[TBL] [Abstract][Full Text] [Related]
35. FTY720 ameliorates experimental autoimmune neuritis by inhibition of lymphocyte and monocyte infiltration into peripheral nerves.
Zhang Z; Zhang ZY; Fauser U; Schluesener HJ
Exp Neurol; 2008 Apr; 210(2):681-90. PubMed ID: 18261728
[TBL] [Abstract][Full Text] [Related]
36. Immunology: Surprising side effects.
Bevan MJ; Fink PJ
Nature; 2008 Aug; 454(7206):837-8. PubMed ID: 18704076
[No Abstract] [Full Text] [Related]
37. Sphingosine 1-phosphate receptor agonism impairs skin dendritic cell migration and homing to secondary lymphoid tissue: association with prolonged allograft survival.
Lan YY; Tokita D; Wang Z; Wang HC; Zhan J; Brinkmann V; Thomson AW
Transpl Immunol; 2008 Nov; 20(1-2):88-94. PubMed ID: 18694829
[TBL] [Abstract][Full Text] [Related]
38. (R)-FTY720 methyl ether is a specific sphingosine kinase 2 inhibitor: Effect on sphingosine kinase 2 expression in HEK 293 cells and actin rearrangement and survival of MCF-7 breast cancer cells.
Lim KG; Sun C; Bittman R; Pyne NJ; Pyne S
Cell Signal; 2011 Oct; 23(10):1590-5. PubMed ID: 21620961
[TBL] [Abstract][Full Text] [Related]
39. FTY720 inhibits tumor growth and enhances the tumor-suppressive effect of topotecan in neuroblastoma by interfering with the sphingolipid signaling pathway.
Li MH; Hla T; Ferrer F
Pediatr Blood Cancer; 2013 Sep; 60(9):1418-23. PubMed ID: 23704073
[TBL] [Abstract][Full Text] [Related]
40. Ceramide synthesis is modulated by the sphingosine analog FTY720 via a mixture of uncompetitive and noncompetitive inhibition in an Acyl-CoA chain length-dependent manner.
Lahiri S; Park H; Laviad EL; Lu X; Bittman R; Futerman AH
J Biol Chem; 2009 Jun; 284(24):16090-16098. PubMed ID: 19357080
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
